ArticleBMC women's health2026
The genetic association of miR-34a-5p rs72631823 with the susceptibility to obstetric antiphospholipid syndrome.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstetric antiphospholipid syndrome (OAPS) is a complex autoimmune disorder affecting women. miR-34a-5p is upregulated in APS patients, yet the role of functional pre-miR-34a rs72631823 polymorphism in OAPS susceptibility and outcomes remains unexplored.
methodsThis case-control study collected 182 OAPS patients and 188 matched healthy pregnant women (confirmed aPL-negative). The rs72631823 polymorphism was genotyped by TaqMan method. Relative miR-34a-5p level was detected by RT-qPCR. Associations were assessed using Chi-square tests and multivariable logistic regression, presented by odds ratios (ORs) with 95% confidence intervals (CIs). The diagnostic value of miR-34a-5p was evaluated by a receiver operating characteristic (ROC) curve. Bioinformatics analysis of miR-34a-5p target genes was performed using miRDB, TargetScan, and ENCORI databases, followed by GO/KEGG enrichment analysis.
resultsrs72631823 AA genotype was independently correlated with increased OAPS risk (adjusted OR = 3.002, 95% CI = 1.189-7.581, P = 0.020), and exhibited a dose-dependent effect on miR-34a-5p expression. The rs72631823 was correlated with a higher risk of poor maternal (AA vs. GG: adjusted OR = 3.767, 95% CI = 1.419-10.003, P = 0.008) and infant outcomes (AA vs. GG: adjusted OR = 2.957, 95% CI = 1.059-8.258, P = 0.039). miR-34a-5p demonstrated promising discriminative ability for OAPS (AUC = 0.859, 95% CI = 0.821-0.897, sensitivity = 79.12%, specificity = 77.66%). Exploratory bioinformatics analysis suggested that miR-34a-5p targets were enriched in Wnt signaling, MAPK pathway, and vascular development. These computational findings provide a plausible biological context and generate hypotheses regarding its potential role in OAPS.
conclusionmiR-34a-5p rs72631823 polymorphism is associated with enhanced miR-34a-5p expression. This increased expression is associated with pro-inflammatory and pro-thrombotic pathways, correlating with an increased risk of OAPS susceptibility and predicting poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.